Apr. 10 at 8:10 AM
$HRTX
2026 Bull Case & M&A Signal
1️⃣ VALUATION: Market Cap ~
$150M vs
$173M-
$183M 2026 Rev Guidance. Trading <0.9x Sales (Biotech avg 3x-5x).
2️⃣ THE TAX TREASURE (NOL):
$1.37B in Net Operating Losses = ~
$288M real tax savings (at 21% rate). THE TAX CREDIT ALONE IS WORTH 2X THE MARKET CAP. Buyer pays "less than zero" for operations.
3️⃣ NOPAIN ACT: Zynrelef now reimbursed outside the bundle (ASP + 6%). Hospitals PROFIT from using it. J-Code assigned = seamless billing. Non-opioid shift is the huge tailwind.
4️⃣ OWNERSHIP & DEFENSE: 80%+ Institutional (Rubric 15.9%, Clearline Capitale 6.49%, Adage 6.1%). NOL shielding: Poison Pill at 4.99% prevents hostile takeovers, preserving tax value for a friendly M&A.
5️⃣ THE CLUE: April 6, 2026 SEC 8-K updated CEO Golden Parachute (200% salary + equity vesting on acquisition). Company is clearly being dressed for sale to the highest bidder (
$PCRX or Big Pharma).
Short Interest 27.5% | DTC ~30 days, massive squeeze potential on any catalyst.
